Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Texas Biotech (TXB) -- Ignore unavailable to you. Want to Upgrade?

To: TradeOfTheDay who wrote (400)	12/22/1997 9:42:00 PM
From: Brander	Read Replies (1) \| Respond to of 834

There is nothing wrong with short selling. It is necessary for an effeicient market. There is something wrong with unethcial behavior, and also calling a company a scam, whithout good evidence. TXB is not a scam.....I very serioulsy doubt that SmithKline Beecham would have antything to do with a scam, and would certainly not enter into an agreement such as this with a scam company: "In August 1997, TBC (TXB) announced a corporate partnership with SmithKline Beecham plc to market and co-develop NOVASTAN(R) in the United States and Canada. The agreement provides for total payments up to $31.5 million of which $16.5 million has been received. In addition, the agreement provides for funding certain development and commercialization expenses and royalties." Brad